

Alegro Health Corp.

TSX VENTURE: **AGO**



May 19, 2005 11:00 ET

ALEGRO Completes Agreement to Provide Ablatherm'C' Prostate Treatment in Canada

TORONTO, ONTARIO--(CCNMatthews - May 19, 2005) - Alegro Health Corp. ("Alegro") (TSX VENTURE:AGO) is pleased to announce that the Company has successfully completed negotiations for the Company's Don Mills Surgical Unit Inc. ("DMSU") to provide the facilities and staff for the innovative Ablatherm(C) prostate cancer treatment. DMSU is currently the only facility in North America where the treatment is being offered to patients.

The Agreement is with Maple Leaf HIFU Company, which holds the exclusive Canadian rights to the Ablatherm(C) process.

The Ablatherm(C) Treatment, a breakthrough, non-invasive procedure, was developed by EDAP TMS S.A. of France and has been in use in Europe with great success since 1993. To date, in excess of 6,500 Ablatherm(C) procedures have been performed, with exceptional results. Despite increased public awareness of prostate cancer prevention and early detection, new cases continue to increase in number. It is estimated that the United States, where the treatment is unavailable, has approximately 250,000 new cases reported annually.

"We are very excited about the opportunity to provide Ablatherm(C) treatment at our DMSU facility" said Dr. William L. Orovan, Superintendent of DMSU. "The Ablatherm(C) treatment is simple, proven and non-invasive. It's great for the patients, great for the company". In addition to being the Chair of the Department of Surgery at McMaster University, and an Alegro Health Corp. director, Dr. Orovan is a practicing Urologist and surgeon.

About ALEGRO HEALTH CORP.

Alegro Health Corp. is a Canadian healthcare service provider. The Company is listed on the TSX Venture Exchange under the symbol "AGO". (www.alegrohealth.com).

The TSX Venture Exchange does not accept responsibility for the adequacy of this news release. ALEGRO cannot guarantee that any forward looking statements contained in this news release will materialize. Nor is it possible for ALEGRO to commit itself to updating information about risks and other factors pertaining to its business that might appear in this or any other disclosure documents.

For more information, please contact

Alegro Health Corp.
Brenda Brasmussen
President and CEO
(416) 496-6166, ext. 328
(416) 499-3520 (FAX)
brasmussen@alegrohealth.com